FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229019561> ?p ?o ?g. }

• W4229019561 abstract "Abstract Background A high percentage of epithelial ovarian cancers (EOC) express the estrogen receptor (ER), which is an ideal target for endocrine therapy. Letrozole is a proven, potent aromatase inhibitor, extensively tested and used in the treatment of ER positive breast cancer. In addition, it seems a potent drug for patients with heavily pre-treated OC as demonstrated in several distinctive settings. However, it has never been evaluated prospectively in a maintenance setting for ovarian cancer after standard of care. The here proposed trial aims to define a population of EOC patients, who would benefit from the effectiveness of the generic agent letrozole, with little expected toxicity and thus beneficial impact on overall quality of life (QoL). Methods In this international multicenter randomized, placebo-controlled phase III trial at clinical centers in Switzerland, Germany and Austria, we plan to include 540 patients with primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low- or high-grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer. Patients are randomized in a 1:1 ratio into two groups: receiving blinded study treatment (letrozole or placebo tablets). When assuming a HR of 0.7, a median PFS of 18 months in the control arm and a median PFS of 25.7 months in the treatment arm, a two-sided alpha level of 5%, 3.5 years recruitment and 1.5 years observation time, we expect 330 events to have occurred within these 5 years in the total cohort yielding a power of 90%. Follow-up data for the whole cohort will be collected for up to 10 years and for the low-grade cancer for up to 12 years. Discussion The here proposed randomized phase III trial aims to identify patients with EOC in the maintenance setting, who benefit from the effectiveness of the letrozole, by proving its efficacy whilst maintaining a high standard of QoL due to the limited toxicity expected in comparison to the current alternative drugs on the market for this treatment phase. Trial registration This trial is registered at clinicaltrials.gov under the identifier NCT04111978 . Registered 02 October 2019." @default.
• W4229019561 created "2022-05-08" @default.
• W4229019561 creator A5004165533 @default.
• W4229019561 creator A5009826260 @default.
• W4229019561 creator A5026212976 @default.
• W4229019561 creator A5034695241 @default.
• W4229019561 creator A5037820269 @default.
• W4229019561 creator A5047695952 @default.
• W4229019561 creator A5057030543 @default.
• W4229019561 creator A5060914681 @default.
• W4229019561 creator A5069886120 @default.
• W4229019561 creator A5076400607 @default.
• W4229019561 creator A5086907081 @default.
• W4229019561 creator A5090489400 @default.
• W4229019561 date "2022-05-06" @default.
• W4229019561 modified "2023-10-13" @default.
• W4229019561 title "Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial" @default.
• W4229019561 cites W1509047972 @default.
• W4229019561 cites W1817833980 @default.
• W4229019561 cites W1912950221 @default.
• W4229019561 cites W1943320567 @default.
• W4229019561 cites W1946355969 @default.
• W4229019561 cites W1994046098 @default.
• W4229019561 cites W2003929214 @default.
• W4229019561 cites W2007343138 @default.
• W4229019561 cites W2009971333 @default.
• W4229019561 cites W2012695246 @default.
• W4229019561 cites W2033737465 @default.
• W4229019561 cites W2071537832 @default.
• W4229019561 cites W2075369275 @default.
• W4229019561 cites W2091634670 @default.
• W4229019561 cites W2098995301 @default.
• W4229019561 cites W2102306754 @default.
• W4229019561 cites W2113122060 @default.
• W4229019561 cites W2133537644 @default.
• W4229019561 cites W2135947389 @default.
• W4229019561 cites W2151509048 @default.
• W4229019561 cites W2151981428 @default.
• W4229019561 cites W2153954237 @default.
• W4229019561 cites W2162645859 @default.
• W4229019561 cites W2214665719 @default.
• W4229019561 cites W2293618284 @default.
• W4229019561 cites W2346624277 @default.
• W4229019561 cites W2408940431 @default.
• W4229019561 cites W2562656542 @default.
• W4229019561 cites W2569695585 @default.
• W4229019561 cites W2581347009 @default.
• W4229019561 cites W2590528754 @default.
• W4229019561 cites W2625393838 @default.
• W4229019561 cites W2736265970 @default.
• W4229019561 cites W2754327139 @default.
• W4229019561 cites W2770938811 @default.
• W4229019561 cites W2789554022 @default.
• W4229019561 cites W2805916993 @default.
• W4229019561 cites W2895799603 @default.
• W4229019561 cites W2897430921 @default.
• W4229019561 cites W2913578326 @default.
• W4229019561 cites W2921533031 @default.
• W4229019561 cites W2928272864 @default.
• W4229019561 cites W2938211811 @default.
• W4229019561 cites W2943864790 @default.
• W4229019561 cites W2954881946 @default.
• W4229019561 cites W2965546441 @default.
• W4229019561 cites W2975141952 @default.
• W4229019561 cites W2976139792 @default.
• W4229019561 cites W2994977341 @default.
• W4229019561 cites W2999409656 @default.
• W4229019561 cites W3116765306 @default.
• W4229019561 doi "https://doi.org/10.1186/s12885-022-09555-8" @default.
• W4229019561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35524184" @default.
• W4229019561 hasPublicationYear "2022" @default.
• W4229019561 type Work @default.
• W4229019561 citedByCount "4" @default.
• W4229019561 countsByYear W42290195612023 @default.
• W4229019561 crossrefType "journal-article" @default.
• W4229019561 hasAuthorship W4229019561A5004165533 @default.
• W4229019561 hasAuthorship W4229019561A5009826260 @default.
• W4229019561 hasAuthorship W4229019561A5026212976 @default.
• W4229019561 hasAuthorship W4229019561A5034695241 @default.
• W4229019561 hasAuthorship W4229019561A5037820269 @default.
• W4229019561 hasAuthorship W4229019561A5047695952 @default.
• W4229019561 hasAuthorship W4229019561A5057030543 @default.
• W4229019561 hasAuthorship W4229019561A5060914681 @default.
• W4229019561 hasAuthorship W4229019561A5069886120 @default.
• W4229019561 hasAuthorship W4229019561A5076400607 @default.
• W4229019561 hasAuthorship W4229019561A5086907081 @default.
• W4229019561 hasAuthorship W4229019561A5090489400 @default.
• W4229019561 hasBestOaLocation W42290195611 @default.
• W4229019561 hasConcept C121608353 @default.
• W4229019561 hasConcept C126322002 @default.
• W4229019561 hasConcept C142724271 @default.
• W4229019561 hasConcept C143998085 @default.
• W4229019561 hasConcept C168563851 @default.
• W4229019561 hasConcept C203092338 @default.
• W4229019561 hasConcept C204787440 @default.
• W4229019561 hasConcept C27081682 @default.
• W4229019561 hasConcept C2777176818 @default.
• W4229019561 hasConcept C2778504769 @default.
• W4229019561 hasConcept C2778812593 @default.
• W4229019561 hasConcept C2780427987 @default.

• next